ProfileGDS5678 / 1456595_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 46% 44% 44% 44% 50% 45% 46% 43% 43% 44% 44% 43% 44% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1304446
GSM967853U87-EV human glioblastoma xenograft - Control 23.0158344
GSM967854U87-EV human glioblastoma xenograft - Control 33.0133144
GSM967855U87-EV human glioblastoma xenograft - Control 42.9741144
GSM967856U87-EV human glioblastoma xenograft - Control 53.1500150
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1450945
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1610346
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9848943
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9657743
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9987244
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0227944
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9533143
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0305344
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9908543